Rabbit Recombinant Monoclonal AASS antibody. Carrier free. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
IP | WB | IHC-P | ICC/IF | |
---|---|---|---|---|
Human | Not recommended | Tested | Not recommended | Not recommended |
Mouse | Not recommended | Predicted | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info - | Notes - |
Bifunctional enzyme that catalyzes the first two steps in lysine degradation.
LKR/SDH, AASS
Rabbit Recombinant Monoclonal AASS antibody. Carrier free. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
ab249108 is the carrier-free version of Anti-AASS antibody [EPR9145(B)] ab154800.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
The AASS also known as Aminoadipate-semialdehyde Synthase is a mitochondrial enzyme that plays a role in lysine degradation. It has alternative names like LKRSDH or Lysine Ketoglutarate Reductase/Saccharopine Dehydrogenase. AASS is a bifunctional enzyme that catalyzes two sequential reactions in lysine catabolism. The first reaction converts lysine into saccharopine and the second converts saccharopine to aminoadipate semialdehyde. The protein possesses an approximate mass of 125 kDa. The expression of AASS occurs mainly in liver and kidney tissues although it can be detected at lower levels in other organs.
Enzymes like AASS are critical in the metabolism of amino acids particularly within the lysine degradation pathway. The AASS enzyme does not form a larger complex but its function is essential for preventing lysine accumulation in cells. When lysine gets degraded it assists in maintaining cellular homeostasis by producing metabolites necessary for energy production and other metabolic processes. AASS functions independently without forming catalytic subunits with other proteins.
Lysine degradation involves AASS as a significant player. This pathway leads to the production of acetyl-CoA an essential molecule in the citric acid cycle and energy production. Another important pathway involving AASS is the production of glutaryl-CoA. During these pathways AASS-related proteins include other enzymes like saccharopine reductase and dehydrogenase which participate sequentially to manage amino acid breakdown.
Abnormal AASS function is associated with hyperlysinemia and saccharopinuria. Hyperlysinemia results from disrupted lysine degradation leading to excess lysine in the blood. Researchers have noted that AASS mutations may impact lysine metabolism causing these conditions. In comparison saccharopinuria characterized by excess saccharopine in urine directly connects to inadequate AASS activity. These conditions highlight how changes in AASS function can cause metabolic imbalances leading to disease.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-AASS antibody [EPR9145(B)] ab154800, the same antibody clone in a different buffer formulation.
All lanes: Western blot - Anti-AASS antibody [EPR9145(B)] (Anti-AASS antibody [EPR9145(B)] ab154800) at 1/1000 dilution
Lane 1: HeLa lysate at 10 µg
Lane 2: Fetal liver lysate at 10 µg
Lane 3: HUVEC lysate at 10 µg
Lane 4: HepG2 lysate at 10 µg
Lane 5: 293T lysate at 10 µg
Predicted band size: 102 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com